![COVID-19 reflections: the lessons learnt from the pandemic](http://www.imperial.ac.uk/ImageCropToolT4/imageTool/uploaded-images/newseventsimage_1612178110772_featurenews2012_x1.jpg)
![shadow](http://www.imperial.ac.uk/assets/news/img/image_shadow_sidebar.png)
Video
COVID-19 reflections
COVID-19 reflections: the lessons learnt from the pandemic
Imperial researchers reflect on the lessons they will take away from the pandemic.
Video
COVID-19 reflections: the lessons learnt from the pandemic
Imperial researchers reflect on the lessons they will take away from the pandemic.
COVID Vaccine Trial Participants at Imperial CRF share their Experience
When the pandemic hit, nearly all the resources at the Imperial Clinical Research Facility (CRF) were directed to help tackle COVID-19.
Vaccines prevented 37 million deaths in LMICs in the last 20 years
Vaccine programmes in low- and middle-income countries have prevented 37 million deaths in the last 20 years alone – 36 million in children under 5.
Imperial vaccine tech to target COVID mutations and booster doses
Imperial is focusing its RNA vaccine technology to target SARS-CoV-2 mutations, boosters and thermostability rather than an immediate efficacy trial.
Vaccines may not signal immediate end to epidemic, researchers say
The vaccine rollout may not signal an immediate end to the Covid-19 epidemic, according to latest modeling from Imperial’s Covid-19 Response Team.
Vaccine collaboration could overcome cold chain issues for RNA-based vaccines
Imperial vaccine researchers are collaborating with industry partners to develop RNA vaccines stable at temperatures up to 40C.
COVID-19 immunity lasts over 4 months, but antibody and T cells can “uncouple"
Majority carry neutralizing antibodies 16-18 weeks after mild or asymptomatic SARS-CoV-2 infection, but antibody and T cell responses can "uncouple".
2
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2
The first clinical efficacy results of ChAdOx1nCoV-19
Feature
Q&A: Cold chains, COVID-19 vaccines and reaching low-income countries
Many low-income countries lack the infrastructure to deliver vaccines effectively, so how can we ensure COVID-19 vaccines are accessible for all?
3
Vaccines give us light at end of the tunnel, Neil Ferguson tells Paris Forum
Imperial’s Professor Neil Ferguson says that the promise of effective COVID-19 vaccines is very encouraging but we may need restrictions until then.